Predictors of secondary revascularization after coronary artery bypass graft surgery and role of dual antiplatelet therapy

Table 4 Pre- and Post-CABG medications and surgical variables in AMT vs. DAPT groups

Variable	AMT (N)	DAPT (N)	p-value
Pre-CABG Medications (n)
ASA	682 (67.9%)	1,031 (70.8%)	0.118
P2Y12 receptor antagonist	156 (15.5%)	437 (30.0%)	< 0.001
Surgical Variables
On-Pump surgery (n)	679 (68.5%)	1,124 (79.2%)	< 0.001
Surgery duration (min)	185.66 ± 55.87	210.15 ± 70.27	< 0.001
SV Graft	2.28 ± 1.00	2.07 ± 1.00	< 0.001
LIMA grafts	0.94 ± 0.28	0.89 ± 0.36	< 0.001
Radial Artery grafts	0.01 ± 0.11	0.02 ± 0.14	0.238
Post-CABG Medications (n)
BB	887 (88.3%)	1,273 (87.3%)	0.482
ACE-I/ARB	531 (52.8%)	837 (57.4%)	0.025
AAD	227 (22.6%)	485 (33.3%)	< 0.001
CCB	165 (16.4%)	277 (19.0%)	0.101
Statin	870 (86.6%)	1,322 (90.7%)	0.001

Values are n (%) or n, unless otherwise indicated.
AMT = aspirin monotherapy; DAPT = dual antiplatelet therapy; BMI = body mass index; CVA = cerebrovascular accident; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; MI = myocardial infarction; CHF = congestive heart failure; PAD = peripheral arterial disease; GFR = glomerular filtration rate; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; ASA = aspirin; BB = beta-blocker; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; AAD = antiarrhythmic drugs; CCB = calcium channel blocker; LIMA = left internal mammary artery; SV = saphenous vein

ISSN: 1749-8090